Yes

Antihistamine

Perennial and seasonal allergic rhinitis and other allergic symptoms including urticaria

B

Hypersensitivity to tripelennamine or any component

Use with caution in patients with narrow-angle glaucoma, bladder neck obstruction, symptomatic prostate hypertrophy, asthmatic attacks, and stenosing peptic ulcer

>10%:

Central nervous system: Slight to moderate drowsiness

Respiratory: Thickening of bronchial secretions

1% to 10%:

Central nervous system: Headache, fatigue, nervousness, dizziness

Gastrointestinal: Appetite increase, weight gain, nausea, diarrhea, abdominal pain, xerostomia

Neuromuscular & skeletal: Arthralgia

Respiratory: Pharyngitis

<1%: Edema, palpitations, hypotension, depression, sedation, paradoxical excitement, insomnia, angioedema, photosensitivity, rash, urinary retention, hepatitis, myalgia, paresthesia, tremor, blurred vision, bronchospasm, epistaxis

Symptoms of overdose include CNS stimulation or depression; flushed skin, mydriasis, ataxia, athetosis, dry mouth

There is no specific treatment for an antihistamine overdose, however, most of its clinical toxicity is due to anticholinergic effects. For anticholinergic overdose with severe life-threatening symptoms, physostigmine 1-2 mg (0.5 mg or 0.02 mg/kg for children) I.V., slowly may be given to reverse these effects.

Increased effect/toxicity with alcohol, CNS depressants, MAO inhibitors

Competes with histamine for H₁-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract

Onset of antihistaminic effect: Within 15-30 minutes

Duration: 4-6 hours (up to 8 hours with PBZ-SR®)

Metabolism: Almost completely in the liver

Elimination: In urine

Oral:

Adults: 25-50 mg every 4-6 hours, extended release tablets 100 mg morning and evening up to 100 mg every 8 hours

Alcohol: Additive CNS effect, avoid use

Drowsiness is common; may cause nervousness or dizziness; may rarely cause insomnia, depression, or paradoxical excitement

Concurrent use with psychotropics may produce additive sedation

No information available to require special precautions

Chronic use of antihistamines will inhibit salivary flow, particularly in elderly patients; this may contribute to periodontal disease and oral discomfort

Take as directed; do not exceed recommended dose. Avoid use of other depressants, alcohol, or sleep-inducing medications unless approved by prescriber. You may experience drowsiness or dizziness (use caution when driving or engaging in tasks requiring alertness until response to drug is known); or dry mouth, nausea, or abdominal discomfort (frequent small meals, frequent mouth care, chewing gum, or sucking hard candy may help). Report persistent dizziness, sedation, or agitation; chest pain, rapid heartbeat, or palpitations; difficulty breathing; changes in urinary pattern; yellowing of skin or eyes; dark urine or pale stool; or lack of improvement or worsening or condition. Breast-feeding precautions: Do not breast-feed.

Raise bed rails, institute safety measures, assist with ambulation

Elixir, as citrate: 37.5 mg/5 mL [equivalent to 25 mg hydrochloride] (473 mL)

Tablet, as hydrochloride: 25 mg, 50 mg

Tablet, extended release, as hydrochloride: 100 mg

Monforte JR, Gault R, Smialek J, et al, "Toxicological and Pathological Findings in Fatalities Involving Pentazocine and Tripelennamine," J Forensic Sci, 1983, 28(1):90-101.

Yeh SY, Todd GD, Johnson RE, et al, "The Pharmacokinetics of Pentazocine and Tripelennamine," Clin Pharmacol Ther, 1986, 39(6):669-76.